Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 259-265

  Panichakul, Tasanee ^a,d   Intachote, Pakamas ^a   Wongkajorsilp, Adisak ^b   Sripa, Banchob ^c   Sirisinha, Stitaya ^d  

^a Laboratory of Immunology   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Apoptosis; cFLIP; Cholangiocarcinoma; Mcl 1; TRAIL; Triptolide

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN; PROTEIN MCL 1; TRIPTERYGIUM WILFORDII EXTRACT; TRIPTOLIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 8; CASPASES; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DITERPENES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; MEMBRANE GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM PROTEINS; PHENANTHRENES; PROTO-ONCOGENE PROTEINS C-BCL-2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 32144455416     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C and Smith CA: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 277: 12687-12690, 1996.
3. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
4. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR and Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567, 2000.
5. Almasan A and Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348, 2003.
6. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997.
7. Pan G, Ni J, Yu G, Wei YF and Dixit VM: TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett 424: 41-45, 1998.
8. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC and Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363-14367, 1998.
9. Watanapa P and Watanapa WB: Liver fluke-associated cholangiocarcinoma. Brit J Surg 89: 962-970, 2002.
10. Gores GJ: Cholangiocarcinoma: current concepts and insights. Hepatology 37: 961-969, 2003.
11. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P and Thomas HC: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Heptol 37: 806-813, 2002.
12. Davila JA and El-Serag HB: Cholangiocarcinoma: the "other" liver cancer on the rise. Am J Gastroenterol 97: 3199-3200, 2002.
13. Shimada M, Takenaka K, Kawahara N, Yamamoto K, Shirabe K, Maehara Y and Sugimachi K: Chemosensitivity in primary liver cancers: evaluation of the correlation between chemosensitivity and clinicopathological factors. Hepatogastroenterology 43: 1159-1164, 1996.
14. Moradpour D and Wands JR: Hepatic oncogenesis. Tumors of the liver. In: Hepatology: A Texbook of Liver Disease Zakim D, Boyer ID (eds). Philadelphia, Saunders, pp. 1490-1512, 1996.
15. Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR and Sugimachi K: Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology 32: 523-527, 2000.
16. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH and Gores GJ: Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 64: 3517-3524, 2004.
17. Panka DJ, Mano T, Suhara T, Walsh K and Mier JW: Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276: 6893-6896, 2001.
18. Kreuz S, Siegmund D, Scheurich P and Wajant H: NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 21: 3964-3973, 2001.
19. Jonsson G, Paulie S and Grandien A: High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res 23: 1213-1218, 2003.
20. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW and Lee BL: Upregulation of FLIPs by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94: 1066-1073, 2003.
21. Dierbi M, Darreh-Shori T, Zhivotovsky B and Grandien A: Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms. Scand J Immunol 54: 180-189, 2001.
22. Bae J, Leo CP, Hsu SY and Hsueh AJW: Mcl-1S, a splicing variant of the antiapoptotic Bcl-2 family member Mcl-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 33: 25255-25261, 2000.
23. Baekelandt M, Holm R, Nesland JM, Trope CG and Kristensen GB: Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol 18: 3775-3781, 2000.
24. Backus HHJ, van Kiel MGH, van Groeningen, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM and Peters GJ: Rb, Mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 12: 779-785, 2001.
25. O'Driscoll L, Cronin D, Kennedy SM, Purcell R, Linehan R, Glynn S, Larkin A, Scanlon K, Mcdermott EW, Hill AD, O'Higgins NJ, Parkinson M and Clynes M: Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Res 24: 473-482, 2004.
26. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E and Dimanche-Boitrel MT: Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 22: 1807-1816, 2003.
27. Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC and Schmid RA: PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22: 5427-5435, 2003.
28. Rohn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H and Weller M: CCNU-dependent potentiation of TRAIL/Apo2L-indued apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c. Oncogene 20: 4128-4137, 2001.
29. Panichakul T, Wanun T, Reutrakul V and Sirisinha S: Synergistic cytotoxicity and apoptosis induced in human cholangiocarcinoma cell lines by a combined treatment with tumor necrosis factor-alpha (TNF-α) and triptolide. Asian Pacific J Allergy Immunol 20: 167-173, 2002.
30. Lee KY, Park JS, Jee YK and Rosen GD: Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-κB activation. Exp Mol Med 34: 462-468, 2002.
31. Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, Ratanarapee S and Pausawasdi A: Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Asian Pacific J Allergy Immunol 9: 153-157, 1991.
32. Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V, Sangsuwan R and Sirisinha S: Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamster. Cancer Lett 133: 169-175, 1998.
33. Catlett IM, Xie P, Hostager BS and Bishop G: Signaling through MHC class II molecules blocks CD95-induced apoptosis. J Immunol 766: 6019-6024, 2001.
34. Ruiz-Ruiz C and Lopez-Rivas A: Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-γ in human breast tumour cells. Biochem J 365: 825-832, 2002.